FREMONT, Calif.--(BUSINESS WIRE)--Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Michael Mydra has joined the company as Senior Vice President of Reimbursement and Market Access.

加利福尼亚州弗里蒙特（商业新闻短讯）--创新医疗器械公司Moximed今天宣布，Michael Mydra已加入该公司，担任报销和市场准入高级副总裁。Moximed致力于提高膝关节骨性关节炎（OA）患者的护理标准。

“Michael has demonstrated the ability to achieve coding, coverage, and payment for multiple innovative medical technologies,” said Chris Gleason, President and CEO of Moximed. “He is a tremendous addition to the Moximed team. The experience he has gained from establishing five Category I CPT codes will be instrumental as we expand access of the MISHA® Knee System.”.

Moximed总裁兼首席执行官克里斯·格里森（ChrisGleason）表示：“迈克尔已经证明了为多种创新医疗技术实现编码、覆盖和支付的能力。”。“他是Moximed团队的一个巨大补充。他从建立五个I类CPT代码中获得的经验将有助于我们扩大MISHA®膝关节系统的使用范围。”。

Prior to joining Moximed, Michael served as the Senior Vice President of Reimbursement and Market Access at PainTEQ, Inc. Michael previously held reimbursement and market access leadership roles at multiple novel medical technology companies, including: Sanarus Medical, Vertos Medical, SI-BONE, Boston Scientific and Profound Medical..

在加入Moximed之前，Michael曾担任PainTEQ，Inc.报销和市场准入高级副总裁。Michael曾在多家新型医疗技术公司担任报销和市场准入领导职务，包括：Sanarus medical、Vertos medical、SI-BONE、Boston Scientific and Foundant medical。。

“It is an honor to join the talented team at Moximed,” said Michael. “The clinical evidence supporting the MISHA Knee System is robust and will continue to grow. I am eager to help expand access to this disruptive technology as we look to transform the lives of millions of people affected by knee osteoarthritis.”.

迈克尔说：“很荣幸能加入Moximed的天才团队。”。“支持MISHA膝关节系统的临床证据是强有力的，并将继续增长。我渴望帮助扩大这种颠覆性技术的使用范围，因为我们希望改变数百万膝关节骨性关节炎患者的生活。”。

About The MISHA® Knee System

关于MISHA®膝关节系统

Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA..

Moximed的MISHA膝关节系统适用于膝关节内侧OA患者，这些患者未能从以前的治疗中缓解。这些患者继续经历干扰日常活动的疼痛，并且由于年龄或缺乏晚期OA而不符合或不愿意接受关节置换术。。

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease.

当关节的自然减震器，软骨和半月板不再缓冲关节日常活动时，膝关节OA就会发展，导致慢性疼痛和活动受限。许多患有轻度至中度OA的人在他们的黄金工作年份都很健康，并且生活繁忙。对于这些患者来说，全膝关节置换术是一种不情愿的选择，因为它是终末期疾病的终末期治疗方法。

OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life..

没有终末期疾病的OA患者寻求保护膝盖，活动水平和生活质量的选择。。

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery.

已知减轻疼痛的骨关节炎关节的体重可以减轻疼痛并改善功能。MISHA膝关节系统是第一个植入式减震器，它可以在每一步行走时减轻膝关节的重量，减轻疼痛，保持功能，并可能延迟关节置换手术。

The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.1.

。

The MISHA Knee System is FDA cleared.

MISHA膝关节系统已获得FDA批准。

About Moximed

Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss.

Moximed的MISHA膝关节系统技术是十多年临床研究和开发的结果，是第一个用于治疗膝关节内侧骨关节炎（OA）的植入式减震器。凭借经验丰富的医学技术领导和强大的投资者支持，Moximed有望提高数百万膝关节置换术前膝关节OA患者的护理水平和生活质量，这些患者受到膝关节炎疼痛和功能丧失的阻碍。

Moximed is based in Fremont, California..

Moximed总部位于加利福尼亚州弗里蒙特。。

To learn more, visit www.moximed.com.

To learn more, visit www.moximed.com.

1. Morgan OJ, Hillstrom HJ, Ranawat A, Fragomen AT, Rozbruch SR, Hillstrom R. Effects of a Medial Knee Unloading Implant on Tibiofemoral Joint Mechanics During Walking. J Orthop Res. 2019;37(10):2149-2156. doi:10.1002/jor.24379.

。J Orthop Res.2019；37（10）：2149-2156。doi:10.1002/jor.24379。